The University of California, San Diego Pediatric AIDS Clinical Trials Unit (UCSD PACTU) proposes to continue its participation in the Pediatric AIDS Clinical Trials Groups (PACTG) funded through the National Institute of Allergy and Infectious Diseases. The UCSD PACTU and its members have made important contributions to the development, implementation and dissemination of the PACTG research agenda and have hold leadership critical to the success of the Group. The accomplishments of our PACTU have been a result of the cooperative efforts of outstanding laboratory scientists and clinical investigators, dedicated research staff and a highly supportive community. The major contributions of our site to the PACTG include providing leadership at the national level and contributing expertise in anti-retroviral therapy, interruption of perinatal transmission, virology, immunology, pharmacology, opportunistic pathogens and adolescents, and the accrual of significant numbers of patients to clinical trials. UCSD investigators have led numerous protocols, served on a broad range of committees and contributed as members of many protocol teams. The UCSD PACTU has contributed to all of the major studies performed by the PACTG. It has taken part in intensive Phase I, I-II studies as well as large multi-center Phase III studies. It has established an outstanding program for the care, recruitment to clinical studies, and retention of HIV-pregnant women, children and adolescents. The UCSD PACTU has always been among the highest performing sites as assessed by patient accrual into clinical trials, quality of data and availability of specimens. Extension of the UCSD PACTU to include a subsite in Phoenix, Arizona has further expanded out Unit's ability to recruit pregnant women and children into clinical trials from the southwestern United States. We believe that the UCSD PACTU's record of past achievement and its plans for the future will assure that the Unit and its members will continue to make important contributions to all aspects of the PACTG scientific agenda.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-PSS-A (J1))
Program Officer
Welsch, Sue A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Diego
Schools of Medicine
La Jolla
United States
Zip Code
Saitoh, Akihiko; Capparelli, Edmund; Aweeka, Francesca et al. (2010) CYP2C19 genetic variants affect nelfinavir pharmacokinetics and virologic response in HIV-1-infected children receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 54:285-9
Saitoh, Akihiko; Foca, Marc; Viani, Rolando M et al. (2008) Clinical outcomes after an unstructured treatment interruption in children and adolescents with perinatally acquired HIV infection. Pediatrics 121:e513-21
Saitoh, Akihiko; Haas, Richard H; Naviaux, Robert K et al. (2008) Impact of nucleoside reverse transcriptase inhibitors on mitochondrial DNA and RNA in human skeletal muscle cells. Antimicrob Agents Chemother 52:2825-30
Hitti, Jane; Andersen, Janet; McComsey, Grace et al. (2007) Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS Clinical Trials Group A5084. Am J Obstet Gynecol 196:331.e1-7
Saitoh, Akihiko; Sarles, Elizabeth; Capparelli, Edmund et al. (2007) CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. AIDS 21:2191-9
Singh, K K; Spector, S A (2007) Fidelity of whole-genome amplification of blood spot DNA for HLA typing and SNP analyses. Clin Genet 72:156-9
Saitoh, Akihiko; Fletcher, Courtney V; Brundage, Richard et al. (2007) Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism. J Acquir Immune Defic Syndr 45:280-5
Seage 3rd, George R; Buchacz, Kate; Weinberg, Geoffrey A et al. (2006) The Pediatric AIDS Severity Score (PASS): a multidimensional AIDS-severity adjustment for pediatric HIV infection. J Acquir Immune Defic Syndr 43:603-10
Patel, Kunjal; Weinberg, Geoffrey A; Buchacz, Kate et al. (2006) Simple Pediatric AIDS Severity Score (PASS): a pediatric severity score for resource-limited settings. J Acquir Immune Defic Syndr 43:611-7
Saitoh, Akihiko; Singh, Kumud K; Sandall, Sharsti et al. (2006) Association of CD4+ T-lymphocyte counts and new thymic emigrants in HIV-infected children during successful highly active antiretroviral therapy. J Allergy Clin Immunol 117:909-15

Showing the most recent 10 out of 55 publications